Peroral

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform

Vincenzo Villanacci - One of the best experts on this subject based on the ideXlab platform.

Raffaele Manta - One of the best experts on this subject based on the ideXlab platform.

A Karjalainen - One of the best experts on this subject based on the ideXlab platform.

  • Effects of Peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism.
    Clinical endocrinology, 2001
    Co-Authors: A Karjalainen, A C Bäckström, Marita Paassilta, Heikkinen J, M J Savolainen
    Abstract:

    OBJECTIVE Conflicting data have been reported previously on the effects of oestrogen replacement therapy on glucose tolerance, and the effects on glycosylated haemoglobin GHbA1c have been studied only among diabetics. The objective of this studywas to evaluate the effects on glucose and insulin metabolism among nondiabetic women and to compare the outcomes of Peroral and transdermal modes of administration. DESIGN The effects of Peroral oestradiol valerate 2 mg/day with placebo gel were compared to those of transdermal 17β-oestradiol gel (1 mg oestradiol/day) and placebo tablets in a randomised, double-blind, double-dummy study for six months. PATIENTS Seventy-nine hysterectomised, nondiabetic postmenopausal women, 39 women in the Peroral oestrogen group and 40 in the gel group. MEASUREMENTS Oral glucose tolerance tests (OGTT) with blood glucose, serum C-peptide and insulin determinations were performed. GHbA1c, IGF-I and IGFBP-1 were measured at baseline and after six months of therapy. In addition, insulin sensitivity and insulin secretion indices were obtained from OGTT. RESULTS A small significant reduction in the GHbA1c concentration was observed during both Peroral (P 

  • Mechanisms Regulating LDL Metabolism in Subjects on Peroral and Transdermal Estrogen Replacement Therapy
    Arteriosclerosis thrombosis and vascular biology, 2000
    Co-Authors: A Karjalainen, J Heikkinen, M J Savolainen, Ann-christine Bäckström, Y A Kesäniemi
    Abstract:

    Abstract —To study the mechanisms of low density lipoprotein (LDL) cholesterol lowering by Peroral and transdermal estrogen replacement therapy (ERT), 79 hysterectomized postmenopausal women aged 48 to 62 years were randomized in a double-blind double-dummy trial to receive either Peroral estradiol valerate (2 mg/d) or transdermal estradiol gel (1 mg/d) for 6 months. Plasma LDL cholesterol decreased from 4.19±0.83 (mean±SD) to 3.39±0.78 mmol/L ( P

  • Metabolic changes induced by Peroral oestrogen and transdermal oestradiol gel therapy.
    British journal of obstetrics and gynaecology, 1997
    Co-Authors: A Karjalainen, J Heikkinen, M J Savolainen, A C Bäckström, M Salinto, Y A Kesäniemi
    Abstract:

    To investigate changes in plasma lipid and lipoprotein levels induced by Peroral oestrogen replacement and transdermal oestradiol gel therapy. The effects of Peroral oestradiol valerate tablets (2 mg) and placebo gel were compared with 1g transdermal oestradiol gel (1mg oestradiol) and placebo tablets in a randomised, double-blind, double-dummy study for 6 months. Department of Internal Medicine, University of Oulu and Oulu Deaconess Institute, Oulu, Finland. Seventy-nine hysterectomised, postmenopausal women, 39 women in the Peroral oestrogen group and 40 in the gel group. Cholesterol and triglycerides in total plasma and in various lipoprotein fractions, and sex hormones. In the Peroral oestrogen group total and LDL cholesterol were decreased and HDL cholesterol and triglycerides were increased. In the oestradiol gel group plasma total, LDL and VLDL cholesterol and the ratio of LDL/HDL cholesterol were significantly decreased, but no change in HDL cholesterol and triglycerides was observed. Overall the decrease in LDL levels was correlated with the increase in oestrogen levels. Both Peroral and transdermal replacement therapy had beneficial effects on plasma lipids by lowering total and LDL cholesterol and LDL/HDL cholesterol ratio. These changes seem to be associated with changes in oestrogen levels.

  • Metabolic changes induced by Peroral oestrogen and transdermal oestradiol gel therapy.
    BJOG: An International Journal of Obstetrics and Gynaecology, 1997
    Co-Authors: A Karjalainen, J Heikkinen, M J Savolainen, A C Bäckström, M Salinto
    Abstract:

    Objective To investigate changes in plasma lipid and lipoprotein levels induced by Peroral oestrogen replacement and transdermal oestradiol gel therapy. Design The effects of Peroral oestradiol valerate tablets (2 mg) and placebo gel were compared with 1g transdermal oestradiol gel (1mg oestradiol) and placebo tablets in a randomised, double-blind, double-dummy study for 6 months. Setting Department of Internal Medicine, University of Oulu and Oulu Deaconess Institute, Oulu, Finland. Population Seventy-nine hysterectomised, postmenopausal women, 39 women in the Peroral oestrogen group and 40 in the gel group. Main outcome measures Cholesterol and triglycerides in total plasma and in various lipoprotein fractions, and sex hormones. Results In the Peroral oestrogen group total and LDL cholesterol were decreased and HDL cholesterol and triglycerides were increased. In the oestradiol gel group plasma total, LDL and VLDL cholesterol and the ratio of LDL/HDL cholesterol were significantly decreased, but no change in HDL cholesterol and triglycerides was observed. Overall the decrease in LDL levels was correlated with the increase in oestrogen levels. Conclusions Both Peroral and transdermal replacement therapy had beneficial effects on plasma lipids by lowering total and LDL cholesterol and LDL/HDL cholesterol ratio. These changes seem to be associated with changes in oestrogen levels.

Jong Ho Moon - One of the best experts on this subject based on the ideXlab platform.

  • therapeutic role of direct Peroral cholangioscopy using an ultra slim upper endoscope
    Journal of Hepato-biliary-pancreatic Sciences, 2011
    Co-Authors: Jong Ho Moon, Hyun Jong Choi, Bong Min Ko
    Abstract:

    Introduction Peroral cholangioscopy provides direct visualization of the bile duct and facilitates diagnostic procedures and therapeutic intervention. The currently available mother–baby scope system is not widely used because of its disadvantages. Direct Peroral cholangioscopy (POC) with a regular, ultra-slim, upper endoscope can provide a valuable and economic solution for evaluating bile duct lesions, although its therapeutic role in biliary tract disease is uncertain. We assessed the usefulness of direct POC with an ultra-slim endoscope for therapeutic application in patients with biliary diseases.

  • CURRENT STATUS OF DIRECT Peroral CHOLANGIOSCOPY
    Digestive Endoscopy, 2011
    Co-Authors: Takao Itoi, Jong Ho Moon, Irving Waxman
    Abstract:

    Recently, several endoscopists have reported the usefulness of direct Peroral video cholangioscopy for the diagnosis and therapy of bile duct lesions. Although ultra-slim pediatric or Tran nasal video endoscopes are usually used for the direct Peroral video cholangioscopy, direct scope insertion without pretreatment and any assistant is considerably difficult. Based on the previous literatures, intraductal balloon catheter-assisted scope insertion might be relatively reliable method. To overcome the issue on the scope insertion, recently prototype cholangioscope that has short bending section and anchoring balloon catheter for scope replacement and insertion has been developed. In the near future, we could establish the direct Peroral cholangioscopy using new developed technology.

  • initial experience with a prototype Peroral direct cholangioscope to perform intraductal lithotripsy with video
    Gastrointestinal Endoscopy, 2011
    Co-Authors: Takao Itoi, Toshio Kurihara, Kentaro Ishii, Takayoshi Tsuchiya, Takuji Gotoda, Atsushi Sofuni, Shujiro Tsuji, Fumihide Itokawa, Jong Ho Moon
    Abstract:

    F s h Urakami et al1 first reported a Peroral direct cholangiosopy (PDCS) procedure 3 decades ago. Recently, PDCS using ltraslim upper endoscopes has been described for diagnosic and therapeutic purposes.2-9 However, those endoscopes re not dedicated cholangioscopes. This is the first report of he use of a dedicated prototype Peroral direct cholangiocope to fragment a difficult bile duct stone.

M J Savolainen - One of the best experts on this subject based on the ideXlab platform.

  • Effects of Peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism.
    Clinical endocrinology, 2001
    Co-Authors: A Karjalainen, A C Bäckström, Marita Paassilta, Heikkinen J, M J Savolainen
    Abstract:

    OBJECTIVE Conflicting data have been reported previously on the effects of oestrogen replacement therapy on glucose tolerance, and the effects on glycosylated haemoglobin GHbA1c have been studied only among diabetics. The objective of this studywas to evaluate the effects on glucose and insulin metabolism among nondiabetic women and to compare the outcomes of Peroral and transdermal modes of administration. DESIGN The effects of Peroral oestradiol valerate 2 mg/day with placebo gel were compared to those of transdermal 17β-oestradiol gel (1 mg oestradiol/day) and placebo tablets in a randomised, double-blind, double-dummy study for six months. PATIENTS Seventy-nine hysterectomised, nondiabetic postmenopausal women, 39 women in the Peroral oestrogen group and 40 in the gel group. MEASUREMENTS Oral glucose tolerance tests (OGTT) with blood glucose, serum C-peptide and insulin determinations were performed. GHbA1c, IGF-I and IGFBP-1 were measured at baseline and after six months of therapy. In addition, insulin sensitivity and insulin secretion indices were obtained from OGTT. RESULTS A small significant reduction in the GHbA1c concentration was observed during both Peroral (P 

  • Mechanisms Regulating LDL Metabolism in Subjects on Peroral and Transdermal Estrogen Replacement Therapy
    Arteriosclerosis thrombosis and vascular biology, 2000
    Co-Authors: A Karjalainen, J Heikkinen, M J Savolainen, Ann-christine Bäckström, Y A Kesäniemi
    Abstract:

    Abstract —To study the mechanisms of low density lipoprotein (LDL) cholesterol lowering by Peroral and transdermal estrogen replacement therapy (ERT), 79 hysterectomized postmenopausal women aged 48 to 62 years were randomized in a double-blind double-dummy trial to receive either Peroral estradiol valerate (2 mg/d) or transdermal estradiol gel (1 mg/d) for 6 months. Plasma LDL cholesterol decreased from 4.19±0.83 (mean±SD) to 3.39±0.78 mmol/L ( P

  • Metabolic changes induced by Peroral oestrogen and transdermal oestradiol gel therapy.
    British journal of obstetrics and gynaecology, 1997
    Co-Authors: A Karjalainen, J Heikkinen, M J Savolainen, A C Bäckström, M Salinto, Y A Kesäniemi
    Abstract:

    To investigate changes in plasma lipid and lipoprotein levels induced by Peroral oestrogen replacement and transdermal oestradiol gel therapy. The effects of Peroral oestradiol valerate tablets (2 mg) and placebo gel were compared with 1g transdermal oestradiol gel (1mg oestradiol) and placebo tablets in a randomised, double-blind, double-dummy study for 6 months. Department of Internal Medicine, University of Oulu and Oulu Deaconess Institute, Oulu, Finland. Seventy-nine hysterectomised, postmenopausal women, 39 women in the Peroral oestrogen group and 40 in the gel group. Cholesterol and triglycerides in total plasma and in various lipoprotein fractions, and sex hormones. In the Peroral oestrogen group total and LDL cholesterol were decreased and HDL cholesterol and triglycerides were increased. In the oestradiol gel group plasma total, LDL and VLDL cholesterol and the ratio of LDL/HDL cholesterol were significantly decreased, but no change in HDL cholesterol and triglycerides was observed. Overall the decrease in LDL levels was correlated with the increase in oestrogen levels. Both Peroral and transdermal replacement therapy had beneficial effects on plasma lipids by lowering total and LDL cholesterol and LDL/HDL cholesterol ratio. These changes seem to be associated with changes in oestrogen levels.

  • Metabolic changes induced by Peroral oestrogen and transdermal oestradiol gel therapy.
    BJOG: An International Journal of Obstetrics and Gynaecology, 1997
    Co-Authors: A Karjalainen, J Heikkinen, M J Savolainen, A C Bäckström, M Salinto
    Abstract:

    Objective To investigate changes in plasma lipid and lipoprotein levels induced by Peroral oestrogen replacement and transdermal oestradiol gel therapy. Design The effects of Peroral oestradiol valerate tablets (2 mg) and placebo gel were compared with 1g transdermal oestradiol gel (1mg oestradiol) and placebo tablets in a randomised, double-blind, double-dummy study for 6 months. Setting Department of Internal Medicine, University of Oulu and Oulu Deaconess Institute, Oulu, Finland. Population Seventy-nine hysterectomised, postmenopausal women, 39 women in the Peroral oestrogen group and 40 in the gel group. Main outcome measures Cholesterol and triglycerides in total plasma and in various lipoprotein fractions, and sex hormones. Results In the Peroral oestrogen group total and LDL cholesterol were decreased and HDL cholesterol and triglycerides were increased. In the oestradiol gel group plasma total, LDL and VLDL cholesterol and the ratio of LDL/HDL cholesterol were significantly decreased, but no change in HDL cholesterol and triglycerides was observed. Overall the decrease in LDL levels was correlated with the increase in oestrogen levels. Conclusions Both Peroral and transdermal replacement therapy had beneficial effects on plasma lipids by lowering total and LDL cholesterol and LDL/HDL cholesterol ratio. These changes seem to be associated with changes in oestrogen levels.

Peroral - 15 days free trial to Access Experts & Abstracts